Literature DB >> 12086947

Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S.

Christine C Jensen1, Miriam Cnop, Rebecca L Hull, Wilfred Y Fujimoto, Steven E Kahn.   

Abstract

First-degree relatives of individuals with type 2 diabetes are at increased risk of developing hyperglycemia. To examine the prevalence and pathogenesis of abnormal glucose homeostasis in these subjects, 531 first-degree relatives with no known history of diabetes (aged 44.1 +/- 0.7 years; BMI 29.0 +/- 0.3 kg/m(2)) underwent an oral glucose tolerance test (OGTT). Newly identified diabetes was found in 19% (n = 100), and impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) was found in 36% (n = 191). Thus, only 45% (n = 240) had normal glucose tolerance (NGT). The homeostasis model assessment of insulin resistance (HOMA-IR) was used to estimate insulin sensitivity; beta-cell function was quantified as the ratio of the incremental insulin to glucose responses over the first 30 min during the OGTT (DeltaI(30)/DeltaG(30)). This latter measure was also adjusted for insulin sensitivity as it modulates beta-cell function ([DeltaI(30)/DeltaG(30)]/HOMA-IR). Decreasing glucose tolerance was associated with increasing insulin resistance (HOMA: NGT 12.01 +/- 0.54 pmol/mmol; IFG/IGT 16.14 +/- 0.84; diabetes 26.99 +/- 2.62; P < 0.001) and decreasing beta-cell function (DeltaI(30)/DeltaG(30): NGT 157.7 +/- 9.7 pmol/mmol; IFG/IGT 100.4 +/- 5.4; diabetes 57.5 +/- 7.3; P < 0.001). Decreasing beta-cell function was also identified when adjusting this measure for insulin sensitivity ([DeltaI(30)/DeltaG(30)]/HOMA-IR). In all four ethnic groups (African-American, n = 55; Asian-American, n = 66; Caucasian, n = 217; Hispanic-American, n = 193), IFG/IGT and diabetic subjects exhibited progressively increasing insulin resistance and decreasing beta-cell function. The relationships of insulin sensitivity and beta-cell function to glucose disposal, as measured by the incremental glucose area under the curve (AUCg), were examined in the whole cohort. Insulin sensitivity and AUCg were linearly related so that insulin resistance was associated with poorer glucose disposal (r(2) = 0.084, P < 0.001). In contrast, there was a strong inverse curvilinear relationship between beta-cell function and AUCg such that poorer insulin release was associated with poorer glucose disposal (log[DeltaI(30)/DeltaG(30)]: r(2) = 0.29, P < 0.001; log[(DeltaI(30)/DeltaG(30))/HOMA-IR]: r(2) = 0.45, P < 0.001). Thus, abnormal glucose metabolism is common in first-degree relatives of subjects with type 2 diabetes. Both insulin resistance and impaired beta-cell function are associated with impaired glucose metabolism in all ethnic groups, with beta-cell function seeming to be more important in determining glucose disposal.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086947     DOI: 10.2337/diabetes.51.7.2170

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  113 in total

1.  Characterisation of subjects with early abnormalities of glucose tolerance in the Stockholm Diabetes Prevention Programme: the impact of sex and type 2 diabetes heredity.

Authors:  J Kuhl; A Hilding; C G Ostenson; V Grill; S Efendic; P Båvenholm
Journal:  Diabetologia       Date:  2004-12-24       Impact factor: 10.122

2.  A genetic variant of G6PC2 is associated with type 2 diabetes and fasting plasma glucose level in the Chinese population.

Authors:  C Hu; R Zhang; C Wang; X Ma; C Wang; Q Fang; Y Bao; K Xiang; W Jia
Journal:  Diabetologia       Date:  2008-12-13       Impact factor: 10.122

Review 3.  The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality.

Authors:  S E Kahn; S Zraika; K M Utzschneider; R L Hull
Journal:  Diabetologia       Date:  2009-03-27       Impact factor: 10.122

Review 4.  The prevention of type 2 diabetes.

Authors:  Jill P Crandall; William C Knowler; Steven E Kahn; David Marrero; Jose C Florez; George A Bray; Steven M Haffner; Mary Hoskin; David M Nathan
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-05-20

5.  Glucose Metabolism After Gastric Banding and Gastric Bypass in Individuals With Type 2 Diabetes: Weight Loss Effect.

Authors:  Marlena M Holter; Roxanne Dutia; Sarah M Stano; Ronald L Prigeon; Peter Homel; James J McGinty; Scott J Belsley; Christine J Ren; Daniel Rosen; Blandine Laferrère
Journal:  Diabetes Care       Date:  2016-11-08       Impact factor: 19.112

Review 6.  Methods for Measuring Risk for Type 2 Diabetes in Youth: the Oral Glucose Tolerance Test (OGTT).

Authors:  Melinda E Chen; Rebecca S Aguirre; Tamara S Hannon
Journal:  Curr Diab Rep       Date:  2018-06-16       Impact factor: 4.810

7.  Differences in insulin sensitivity, pancreatic beta cell function and circulating adiponectin across glucose tolerance status in Thai obese and non-obese women.

Authors:  La-Or Chailurkit; Suwannee Chanprasertyothin; Wallaya Jongjaroenprasert; Boonsong Ongphiphadhanakul
Journal:  Endocrine       Date:  2008-04-04       Impact factor: 3.633

8.  The changes in early phase insulin secretion in newly diagnosed, drug naive korean prediabetes subjects.

Authors:  Sang Youl Rhee; Joo Young Kim; Suk Chon; You Cheol Hwang; In Kyung Jeong; Seungjoon Oh; Kyu Jeung Ahn; Ho Yeon Chung; Jeong-Taek Woo; Sung Woon Kim; Jin-Woo Kim; Young Seol Kim
Journal:  Korean Diabetes J       Date:  2010-06-30

Review 9.  Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control.

Authors:  Piero Marchetti; Roberto Lupi; Silvia Del Guerra; Marco Bugliani; Valentina D'Aleo; Margherita Occhipinti; Ugo Boggi; Lorella Marselli; Matilde Masini
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

10.  Impact of metabolic syndrome compared with impaired fasting glucose on the development of type 2 diabetes in a general Japanese population: the Hisayama study.

Authors:  Naoko Mukai; Yasufumi Doi; Toshiharu Ninomiya; Jun Hata; Koji Yonemoto; Masanori Iwase; Mitsuo Iida; Yutaka Kiyohara
Journal:  Diabetes Care       Date:  2009-09-03       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.